Tremfya Market to Grow with a CAGR of 7.59% through 2030
Growing
research and development activities in monoclonal antibody therapies, and
expanding patient access to advanced immunology treatments, is
expected to drive the Global Tremfya Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Tremfya Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global Tremfya
Market stood at USD 3.78
Billion in 2024 and is expected to reach USD 5.87 Billion by
2030 with a CAGR of 7.59% during the forecast period. The Global Tremfya Market is progressing
as a result of growing physician preference for next-generation biologics that
specifically target immune system pathways implicated in chronic inflammatory
diseases. Tremfya’s mechanism of selectively inhibiting the p19 subunit of
interleukin-23 has positioned it as a differentiated option in the biologics
segment, offering durable disease control and improved quality of life for
patients. Expanding diagnostic capabilities are enabling earlier identification
of moderate-to-severe cases, increasing the eligible patient pool for advanced
therapies. Healthcare systems in developed markets are increasingly integrating
biologic treatment protocols into standard care, while rising patient advocacy
efforts are improving disease awareness and encouraging timely medical
intervention.
Market
dynamics are also influenced by the emphasis on real-world evidence to validate
clinical trial outcomes, with data supporting Tremfya’s consistent efficacy and
safety across diverse patient populations. Pharmaceutical companies are
adopting innovative patient engagement tools, such as digital health platforms
and adherence tracking technologies, to support treatment continuity. Strategic
market expansion initiatives, including regulatory approvals for new geographic
regions and additional indications, are contributing to wider availability. The
competitive environment is characterized by innovation in drug administration
techniques, with the aim of minimizing patient discomfort and reducing the
overall treatment burden. These factors are fostering a favorable environment
for sustained market momentum.
Significant
growth opportunities lie in exploring Tremfya’s therapeutic potential beyond
psoriasis and psoriatic arthritis, with ongoing trials assessing its efficacy
in conditions such as Crohn’s disease and ulcerative colitis. Expanding its use
in pediatric and geriatric populations represents another untapped avenue,
subject to regulatory approvals. Partnerships with telemedicine providers can
help reach underserved populations, while value-based contracting with insurers
can enhance affordability and adoption. As precision medicine gains traction,
there is potential for integrating genetic and biomarker testing to identify
ideal candidates for Tremfya therapy, thereby improving outcomes and
strengthening its position in the competitive biologics market.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Tremfya Market”
The Global Tremfya
Market is segmented into application, distribution channel, regional
distribution, and company.
Based on the Application,
Psoriatic Arthritis (PsA) emerged as the fastest growing segment in the Global Tremfya
Market during the forecast period. This is driven by increasing awareness and
early diagnosis of this chronic inflammatory condition. PsA affects a
significant portion of patients with psoriasis, causing joint pain, stiffness,
and progressive damage that can severely impact quality of life. Tremfya’s
targeted mechanism as an IL-23 inhibitor has shown promising results in
controlling both skin and joint symptoms, making it an attractive treatment option
for physicians managing moderate-to-severe cases. The growing adoption of
biologics over conventional therapies is further accelerating market growth, as
patients seek effective treatments that offer long-term disease control with
fewer side effects. Expanding clinical evidence demonstrating Tremfya’s
efficacy in reducing joint inflammation, preventing structural damage, and
improving functional outcomes has enhanced physician confidence and
prescription rates. Supportive reimbursement policies and patient assistance
programs are also facilitating access to treatment, especially in developed
healthcare markets.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Tremfya Market during the
forecast period. Increased participation in awareness programs and patient
advocacy initiatives has educated individuals on the benefits of early
intervention and biologic therapies, driving demand for innovative treatments.
Digital health solutions, telemedicine consultations, and mobile healthcare
platforms are enhancing patient engagement, facilitating adherence to complex
biologic regimens, and expanding access to urban and semi-urban populations.
Expansion of local distribution networks and partnerships between multinational
pharmaceutical companies and regional healthcare providers are improving
product availability across the region. Market growth is also supported by
ongoing clinical trials and real-world studies conducted in Asia-Pacific, which
are providing region-specific efficacy and safety data that further encourage
physician adoption. Cultural shifts toward proactive disease management and
increased willingness to invest in long-term therapies are fueling interest in
high-value biologics such as Tremfya.
Major
companies operating in Global Tremfya Market are:
- Johnson
& Johnson Services, Inc.
- Coherus
BioSciences
- Amgen
Inc.
- AbbVie
Inc.
- Novartis
AG
- Eli
Lilly and Company
- Pfizer
Inc.
- AstraZeneca
plc
- Sanofi
S.A.
- Bristol-Myers
Squibb
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Tremfya Market is expanding
due to the growing emphasis on real-world evidence and patient-centered care in
autoimmune disease management. Healthcare providers are increasingly relying on
long-term data to guide treatment decisions, favoring therapies like Tremfya
that demonstrate consistent efficacy, safety, and patient adherence in diverse
populations. Pharmaceutical companies are supporting this trend by investing in
observational studies, registries, and digital monitoring tools to track outcomes
and optimize individualized treatment plans. This approach not only strengthens
physician confidence in prescribing biologics but also encourages patient
engagement and sustained therapy continuity.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Tremfya Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By
Application (Plaque Psoriasis, Psoriatic Arthritis (PsA), Others), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Tremfya Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Tremfya Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com